Neuropore

Our Mission

To discover and develop novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

News

Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

See All News

Events

Neuropore Therapies (NPT^®) Researchers to Present at the Annual Society for Neuroscience Meeting

October November 3rd-7th, 2018 at the San Diego Convention Center

Click here for more information

See All Events

NPT^® Publications

Neuropore publishes paper describing the preclinical in vivo characterization of a small molecule compound targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications